Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Authors: Gordon et al.

Link to paper:

Journal/ Pre-Print: bioRxiv

Key Words: pharmacological therapies, mass spectrometry, proteomics, host response

Research Highlights 

1. Identified 332 high confidence SARS-CoV-2-human protein-protein interactions.

2. Demonstrated that the interacting proteins were highly expressed or enriched in lung tissue

3. Identified 67 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds.


The authors expressed 26 strep-tagged SARS-CoV-2 proteins in the kidney-derived human cell line HEK293T, and used affinity-purified mass-spectrometry to identify 332 host proteins that interact with viral proteins. These host proteins fall in many pathways, including lipid modification and innate immunity. These interactions were not validated in lung cells, but the host proteins were overexpressed in lung relative to other tissues. 69 drugs, including 27 FDA-approved drugs, target these host proteins, though whether they would inhibit or encourage infection is unknown. The authors propose a genetic screen to test whether loss of these drug-targeted host proteins would impact viral infectivity.

Impact for SARS-CoV2/COVID19 research efforts

Understand the virology and/or cell biology of SARS-CoV2/COVID19

Inhibit of SARS-CoV2/COVID19 transmission

Treat of SARS-CoV2/COVID19 positive individuals

Study Type

· In vitro study

Strengths and limitations of the paper

Novelty: Untargeted investigation of the host protein response to Sars-CoV-2

Standing in the field: Robust methods, however needs to be repeated or corroborated by other methods. E.g need to test the potential drug hits in cell culture.

Appropriate statistics: Not applicable

Viral model used: SARS-CoV-2 isolate 2019-nCoV/USA-WA1/2020

Translatability: Identification of an antiviral, but this requires testing in cell culture

Main limitations: The results show that there may be binding of these human proteins with Sars-CoV-2 proteins, but this needs to be repeated, and corroborated by other methods.